Nanocarrier Design for Dual-Targeted Therapy of In-Stent Restenosis.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cardiovascular Research

Background:

• Artery reocclusion (restenosis) after angioplasty is a significant clinical challenge.
• Current therapies for restenosis have limitations in efficacy and site-specific delivery.
• Developing targeted delivery systems is crucial for improving restenosis treatment outcomes.

Purpose of the Study:

• To investigate a dual-targeted strategy for treating in-stent restenosis using drug-loaded magnetizable nanoparticles (MNPs).
• To evaluate the efficacy of MNPs functionalized with a fibrin-avid peptide for enhanced arterial binding and retention.
• To assess the antirestenotic effects of paclitaxel-loaded MNPs in a rat carotid stenting model.

Main Methods:

• Biodegradable MNPs loaded with paclitaxel were synthesized and characterized.
• MNPs were surface-modified with a fibrin-avid peptide for enhanced arterial wall affinity.
• In vitro studies assessed MNP antiproliferative effects on smooth muscle cells.
• In vivo studies in rats evaluated MNP targeting, retention, and antirestenotic efficacy using imaging and histological analysis.

Main Results:

• MNPs were efficiently functionalized without compromising magnetic properties or antiproliferative potency.
• Dual-targeted MNPs demonstrated enhanced localization and retention in stented arteries for up to 7 days.
• Magnetic guidance was the dominant factor in arterial localization.
• Dual-targeted therapy significantly reduced neointima-to-media ratio and % stenosis in a rat restenosis model.

Conclusions:

• Dual-targeted delivery of antirestenotic agents using fibrin-avid MNPs offers a promising new platform for treating in-stent restenosis.
• This approach enables efficient site-specific localization and sustained presence of therapeutic agents.
• The findings support the potential for safe and effective treatment of restenosis with this novel nanoparticle system.